-

Lunaphore highlights novel spatial biology research at SITC 2021

LAUSANNE, Switzerland--(BUSINESS WIRE)--Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced new research from collaborators at the University of Birmingham, who characterized the inflammatory response associated with a complication from maternal COVID-19 infection, using COMET™, Lunaphore’s all-in-one staining and imaging platform for high-throughput, hyperplex immunofluorescence. The results will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place November 10-14, 2021 virtually and in-person at the Walter E. Washington Convention Center in Washington, D.C. Lunaphore will also hold product demonstrations of LabSat® and COMET™ at booth #408.

Using spatial biology tools to characterize COVID-19 placentitis

A proportion of maternal COVID-19 infections are complicated by COVID-19 placentitis, an inflammatory response that often leads to fetal death. However, there has been limited research to-date on the processes that drive this condition and its underlying pathology.

In a sponsored symposium, Matthew Pugh, FRCPath, of the University of Birmingham will discuss how his team used the Lunaphore COMET™ system to conduct a multiplex immunohistochemistry analysis of 30 markers to characterize the processes that drive COVID-19 placentitis. Utilizing spatial biology methods, the present study found that COVID-19 placentitis is characterized by direct infection of the villous trophoblast, histiocytic intervillousitis and associated CXCL10 & interferon mediated inflammation1.

Read the full abstract here and view the presentation details below.

Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting: The morpho-molecular features of COVID-19 placentitis: A high dimensional, multi-omic approach
Date and time: Saturday, November 13; 1:30 – 2:00 p.m. EST | 7:30 – 8:00 p.m. CET
Speaker: Matthew Pugh, FRCPath. (Institute of Immunology and Immunotherapy, University of Birmingham)

In-booth product demonstrations

Lunaphore will also feature its LabSat® and COMET™ spatial biology solutions at booth #408. Live product demonstrations will take place:

  • Friday, November 12; 1:30 – 2:00 p.m. and 6:00-6:30 p.m. EST
  • Saturday, November 13; 1:00 – 1:30 p.m. and 6:00-6:30 p.m. EST

To learn more about LabSat®, please visit: https://lunaphore.com/products/labsat/.

To learn more about COMET™, please visit: https://lunaphore.com/products/comet/.

To find out more about Lunaphore's activities on site, please visit: https://lunaphore.com/news/lunaphore-at-sitc-annual-meeting/.

Disclaimer:

1 The research is not yet published or peer-reviewed.

About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.

Contacts

For further information contact:

Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com

Lunaphore Technologies SA

Details
Headquarters: Lausanne, Switzerland
CEO: Ata Tuna Ciftlik
Employees: 38
Organization: PRI

Release Versions

Contacts

For further information contact:

Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com

Social Media Profiles
More News From Lunaphore Technologies SA

Lunaphore to Get Acquired by Bio-Techne

TOLOCHENAZ, Switzerland & MINNEAPOLIS--(BUSINESS WIRE)--Lunaphore Technologies SA, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has reached an agreement to be acquired by Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The acquisition is anticipated to close in Q3. Founded in 2014 and headquartered i...

Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™

LAUSANNE, Switzerland & DANVERS, Mass.--(BUSINESS WIRE)--Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. CST is a trusted pr...

Lunaphore and Abcam Announce Agreement for Primary Antibody Validation for Use on COMET™, Combining Power of Trusted Antibody Provider With Superior Multiplex Capabilities

LAUSANNE, Switzerland & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and abcam (NASDAQ: ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced an agreement to co-market abcam primary antibodies specifically validated for use on Lunaphore’s COMET™ platform. The agreement will enable researchers to use abca...
Back to Newsroom